Overview
Research indicates that newer oral anticoagulants (NOACs) may offer an unanticipated benefit beyond stroke prevention for individuals diagnosed with Alzheimer’s disease and co-occurring atrial fibrillation. Findings suggest that patients receiving NOACs experienced a decelerated trajectory of cognitive decline when compared with those administered warfarin or those not receiving any anticoagulant therapy.
Findings
- Patients with Alzheimer’s disease and atrial fibrillation who were treated with NOACs exhibited a slower rate of cognitive function decline.
- This observed deceleration in cognitive decline was in comparison to patients utilizing warfarin.
- The slower cognitive decline was also noted when compared to patients not receiving any blood thinners.
- The annual impact on cognitive function was characterized as modest.
- However, this modest annual effect was noted to have the potential to accumulate over an extended period.
Why This Matters
The observed association between NOAC use and a slower rate of cognitive decline in this specific patient population (Alzheimer's and atrial fibrillation) highlights a potential additional therapeutic consideration for managing complex multimorbidity. While the annual effect is modest, its cumulative impact over time could represent a meaningful difference in the progression of cognitive impairment in a vulnerable patient group.